This Podcast is an interview with Michael Baker, CEO and Managing Director of Arovella Therapeutics , a biotechnology company focused on developing cell therapies for cancer treatment. Michael discusses his background, transitioning from a research scientist to venture capital and then joining Arovella in 2020. He explains Arovella's work on CAR-iNKT cell therapies, which involve genetically reprogramming a patient's immune cells to target and kill cancer cells.

Michael highlights the advantages of Arovella's approach over traditional CAR-T cell therapies, including faster manufacturing, lower costs, and the ability to treat multiple patients from a single manufacturing run.

He outlines recent milestones, such as completing the manufacturing process development and scaling up for clinical trials. Michael also discusses the competitive landscape, potential partnerships and acquisitions in the cell therapy sector, target markets, and upcoming milestones for Aravella, including regulatory submissions, animal studies, and exploring new technologies.

This content is factual information only, does not contain financial product advice and has not been prepared in consideration of your personal circumstances or needs. Views shared by individuals are their own personal views and not the views of Sub11. We are not licenced to provide financial product advice and cannot make investment recommendations to you. Investments carry risk. Please consider seeking professional financial advice, and read the relevant disclosure documents, before making any decisions to invest in financial products.